drugset / Trial / NCT00215930
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
53 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Aventis Pharmaceuticals · collabEli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference. In this protocol, the treatment regimen will be assigned based on the patients' tumor molecular profile. A tumor molecular profile analysis will allow the physician to define a specific molecular portrait that shows the genetic basis of the tumor. This analysis results in a detailed report that will determine which chemotherapy will be assigned to the patient.
Timeline
- Start
- 2004-02
- Primary completion
- 2009-10
- Completion
- 2009-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Docetaxel | Small molecule | 40 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | — |
| Subject | Vinorelbine | Small molecule | 45 mg/m2 | — |